We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus.
- Authors
Xu-Ying Pei; Xiang-Yu Zhao; Ying-Jun Chang; Jing Liu; Lan-Ping Xu; Yu Wang; Xiao-Hui Zhang; Wei Han; Yu-Hong Chen; Xiao-Jun Huang; Pei, Xu-Ying; Zhao, Xiang-Yu; Chang, Ying-Jun; Liu, Jing; Xu, Lan-Ping; Wang, Yu; Zhang, Xiao-Hui; Han, Wei; Chen, Yu-Hong; Huang, Xiao-Jun
- Abstract
<bold>Background: </bold>The efficiency and mechanisms of adoptive transfer of cytomegalovirus (CMV)specific T cells for refractory CMV infection after haploidentical stem cell transplantation (haplo-SCT) remain largely unknown.<bold>Methods: </bold>Thirty-two patients with refractory CMV infection who accepted treatment with adoptive CMV-specific T-cell infusion following haplo-SCT were prospectively enrolled. Another 32 patients with nonrefractory CMV infection after haplo-SCT were selected as control subjects. The phenotypical and functional characteristics of CMV-specific T cells were analyzed before and after cellular therapy in the refractory cohort, as well as in the nonrefractory cohort.<bold>Results: </bold>In the refractory cohort, 27 of the 32 treated patients exhibited CMV clearance within 4 weeks after adoptive T-cell transfer without recurrence. The in vivo expansion of CMV-specific T cells and improvements in the cytokine production and proliferation ability of the CMV-specific T cells were observed after cellular therapy. Moreover, a reduced expression of programmed death-1 (PD-1) on CMV-specific T cells was observed. However, in the remaining 5 patients who showed CMV recurrence 4 weeks after transfer, neither the quantity nor the function of CMV-specific T cells was restored.<bold>Conclusions: </bold>The adoptive transfer of CMV-specific T cells promotes quantitative and functional recovery of CMV-specific T cells to guard against refractory CMV infection after haplo-SCT.
- Subjects
CYTOMEGALOVIRUS disease treatment; T cells; STEM cell transplantation; PROGRAMMED cell death 1 receptors; CELLULAR therapy; ANTIVIRAL agents; THERAPEUTICS
- Publication
Journal of Infectious Diseases, 2017, Vol 216, Issue 8, p945
- ISSN
0022-1899
- Publication type
journal article
- DOI
10.1093/infdis/jix357